Stockreport

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant, Inc.  (IMVT) 
PDF Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-14 [Read more]